natgillin/translations-raw huggingface dataset:
2 Fatalities due to sepsis have been reported in patients treated with topotecan (see section 4.4)
2Prijavljeni su smrtni slučajevi u bolesnika liječenih topotekanom (vidjeti dio 4.4).
2 Fatalities due to sepsis have been reported in patients treated with topotecan (see section 4.4)
2Smrtni ishodi zbog sepse prijavljeni su u bolesnika koji su liječeni topotekanom (vidjeti dio 4.4).
2 Fatalities due to sepsis have been reported in patients treated with topotecan (see section 4.4).
2Smrtni ishodi zbog sepse zabilježeni su u bolesnika koji su liječeni topotekanom (vidjeti dio 4.4).
2 film-coated tablets 4 film-coated tablets 8 film-coated tablets
2 filmom obložene tablete 4 filmom obložene tablete 8 filmom obloženih tableta
2 film-coated tablets 4 film-coated tablets 8 film-coated tablets 12 film-coated-tablets
2 filmom obložene tablete 4 filmom obložene tablete 8 filmom obloženih tableta 12 filmom obloženih tableta
2 filter transfer devices
2 naprave za prijenos s filtrom
2 filter transfer devices, 1 disposable 10 ml syringe, 1 venipuncture set, and 1 protective mat.
2 naprave s filtrom za prijenos, 1 štrcaljka od 10 ml za jednokratnu uporabu, 1 set za venepunkciju i 1 zaštitna podloga.
2 Flocculation equivalents; corresponds with ≥ 30 IU/ml guinea pig serum in the Ph.Eur. potency test
2Flokulacijski ekvivalenti, odgovaraju ≥ 30 IJ/ml seruma zamorca u Ph.
2 Fluid collection includes localised oedema, pseudocyst and implant site effusion.
2 Nakupljanje tekućine uključuje lokalizirani edem, pseudocistu i izljev na mjestu implantata.
2 Follow-up analysis was performed with a data cut-off date of 07 March 2014; all p-values are displayed for descriptive purpose only
2 Analiza nakon praćenja provedena je na temelju podataka prikupljenih do 7. ožujka 2014.; sve p-vrijednosti navedene su samo u ilustrativne svrhe
2 For all efficacy endpoints the confidence intervals were 95%, except for HIV-1 RNA Change from baseline which was 97.5%
2Za sve mjere ishoda djelotvornosti, intervali pouzdanosti bili su 95% osim za promjenu HIV-1 RNA u odnosu na početnu vrijednost, gdje je iznosila 97,5%.
2 For further description, please see sub-section “Description of selected adverse reactions”
2 Za dodatni opis, molimo pogledajte odlomak „Opis izabranih nuspojava“
2 for treatment days 7, 9 and 11
2 za dane liječenja 7, 9 i 11
2 Full Analysis Set (FAS) (for POX-MVA-013: Immunogenicity Analysis Set; IAS); 3 Per Protocol Analysis Set (PPS),
Full Analysis Set - FAS) (za POX-MVA-013: skupina ispitanika za analizu imunogenosti; IAS); 3 Analiza ispitanika koji su završili ispitivanje prema protokolu (engl.
2 full turns (10 clicks)
puna okretaja (10 škljocaja)
2 g gel
2 g gela
2 g NexoBrid powder in 20 g gel is applied to a burn wound area of 100 cm2.
2 g praška NexoBrid u 20 g gela nanosi se na površinu opekline od 100 cm2.
2 G TUBE
TUBA OD 2 G
2 g/kg bw
2 g/kg TT
2 Gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite occur most frequently during initiation of therapy and resolve spontaneously in most cases.
2 Gastrointestinalni simptomi poput mučnine, povraćanja, proljeva, boli u abdomenu i gubitka teka najčešće se javljaju na početku liječenja i u većini se slučajeva sami povuku.
2 Histological response defined as a ≥ 2 point decrease in Knodell Necroinflammatory Score from baseline with no worsening of the Knodell Fibrosis Score.
2 Histološki odgovor definiran kao smanjenje Knodellovog nekroinflamatornog skora za ≥2 boda u odnosu na početnu vrijednost, te bez pogoršanja prema skoru fibroze po Knodellu.
2 hours after omeprazole)
2 sata nakon omeprazola)
2 hours after PREZISTA/ritonavir
prije ili 2 sata nakon lijeka
2 hours after raltegravir
2 sata nakon raltegravira
2 hours before raltegravir raltegravir AUC  51 % raltegravir C12 hr  56 %
2 sata prije raltegravira raltegravir AUC  51 % raltegravir C12h  56 % raltegravir Cmax  51
2 hr
2 sata
2 hr
ata
2 Identified adverse reactions of empagliflozin monotherapy
2 Identificirane nuspojave monoterapije empagliflozinom
2 Immunosuppressant therapy could only be discontinued at or after Week 26 at the investigator's discretion if the subject met the clinical response criterion
2 Imunosupresivna terapija mogla se obustaviti samo u 26. tjednu ili kasnije, prema slobodnoj procjeni ispitivača ako je ispitanik ispunio kriterije kliničkog odgovora
2 In clinical studies, response to voriconazole in patients with C glabrata infections was 21% lower compared to C. albicans, C. parapsilosis and C. tropicalis.
2 U kliničkim ispitivanjima je odgovor na vorikonazol u bolesnika s infekcijama uzročnika C. glabrata bio 21% niži u odnosu na one infekcije čiji su uzročnici bili C. albicans, C. parapsilosis i C. tropicalis.
2 In clinical studies, response to voriconazole in patients with C. glabrata infections was 21% lower compared to C. albicans, C. parapsilosis and C. tropicalis.
2 U kliničkim ispitivanjima je odgovor na vorikonazol u bolesnika s infekcijama uzročnika C. glabrata bio 21% niži u odnosu na one infekcije čiji su uzročnici bili C. albicans, C. parapsilosis i C. tropicalis.
2 In insulin-comparator controlled studies in which metformin and a sulphonylurea were concomitant medicinal products, the incidence for these adverse reactions was similar for insulin- and immediate-release exenatide-treated patients.
2 U kontroliranim ispitivanjima s inzulinom kao usporednim lijekom, uz istodobnu primjenu metformina i sulfonilureje, incidencija ovih nuspojava bila je podjednaka u bolesnika liječenih inzulinom i eksenatidom s trenutnim oslobađanjem.
2 in patients randomised to Humalog Mix25 during the first crossover period
2 u bolesnika nasumce raspoređenih da u prvom dijelu ukriženog ispitivanja primaju Humalog Mix25
2 in patients randomised to Liprolog Mix25 during the first crossover period
2 u bolesnika nasumce raspoređenih da u prvom dijelu ukriženog ispitivanja primaju Liprolog Mix25
2 In some cases of myopathy involving raised CPK and muscle symptoms, the patients also presented with elevated transaminases.
2 U nekim slučajevima miopatije koje su uključivale povišenje CPK i mišićne simptome, bolesnici su također imali i povišene transaminaze.
2 In the photoactivated area
2 U fotoaktiviranom području
2 Includes events occurring after first dose of apixaban (post-surgery)
2 Uključuje događaje koji su nastupili nakon prve doze apiksabana (nakon kirurškog zahvata)
2 Includes immune thrombocytopenic purura.
2 Uključuje imunu trombocitopeničnu purpuru.
2 Includes other less common species or species unknown
2 Obuhvaća ostale rjeđe vrste ili nepoznate vrste
2 Includes Stomatitis, Aphthous stomatitis, Mucosal inflammation, Mouth ulceration, Oral mucosa erosion, Mucosal erosion, Mucosal ulceration
2 uključuje stomatitis, aftozni stomatitis, upalu sluznice, ulceraciju usta, eroziju sluznice usta, eroziju sluznice, ulceraciju sluznice
2 Including in-growing eyelashes, excessive growth and thickening of the eyelashes.
2 uključujući rast trepavica prema oku, pojačan rast i zadebljanje trepavica.
2 inhalers (2x120 doses)
2 inhalator (2x120 doza)
2 inhalers (2x60 doses)
2 inhalatora (2x60 doza)
2 inner cartons).
2 unutarnje kutije).
2 International units of beta antitoxin according to Ph.
2 Međunarodna jedinica beta antitoksina prema Ph.Eur.
2 Investigator assessed PFS analysis with data cut-off date of 30 November 2010.
2 Analiza preživljenja bez progresije bolesti po procjeni ispitivača, prema podacima do 30. studenog 2010.
2 Isolated cases reported in post-marketing experience
2 Izolirani slučajevi prijavljeni u postmarketinškom iskustvu.
2 IU International Unit
2 IU Internacionalna jedinica
2 kg/tonne*
2 kg/tona
2 litres gas cylinder
Spremnik s plinom od 2 litre
2 litres of liquid per day).
2 litre tekućine dnevno).
2 Lowest concentration, which completely inhibits visible growth of at least 90 % of isolates
2 Najniža koncentracija, koja potpuno inhibira vidljiv rast najmanje 90% izolata
2 matrices of 4.8 x 4.8 cm
2 matriks od 4.8 x 4.8 cm
2 Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline.
2 Srednja vrijednost porasta vrijednosti lipida natašte (ukupni kolesterol, LDL kolesterol i trigliceridi) bila je veća u bolesnika bez dokazane disregulacije lipida na početku.
2 Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline.
Promjene vrijednosti triglicerida natašte od početnih graničnih vrijednosti (≥ 1,69
2 mg
Tadalafil
2 mg aflibercept).
2 mg aflibercepta).
2 mg capsule shell contains gelatin, titanium dioxide (E171), indigotine (E132), yellow iron oxide (E172), erythrosin (E127) and white ink.
Ovojnica kapsule od 2 mg sadrži: želatinu, titanijev dioksid (E171), indigotin (E132), željezov oksid, žuti (E172), eritrozin (E127) i bijelu tintu.
2 mg capsule shell contains: white ink – shellac, titanium dioxide (E171), simethicone, propylene glycol (E1520) and ammonium hydroxide (E527).
Ovojnica kapsule od 2 mg sadrži: bijelu tintu - šelak, titanijev dioksid (E171), simetikon, propilenglikol (E1520) i amonijev hidroksid (E 527).
2 mg Q8 A
2 mg svaka
2 mg Q8 A
2 mg svakih
2 mg Q8 A
2 mg svakih 8 tjedana A
2 mg Q8 A
2 mg svakih 8 tjedanaA
2 mg single dose
2 mg pojedinačna doza
2 mg single dose4
doza od 2 mg4
2 mg tablet: pale orange, round, biconvex tablets of 6 mm, marked with the Bayer cross on one side and 2 and an “R” on the other side.
2 mg tableta: blijedonarančaste, okrugle, bikonveksne tablete od 6 mm, označene Bayerovim križem s jedne strane te brojem 2 i slovom “R” s druge strane.
2 mg, 5 mg, 10 mg and 20 mg hard capsules: Apotek Produktion & Laboratorier AB Prismavägen 2
2 mg, 5 mg, 10 mg i 20 mg tvrde kapsule: Apotek Produktion & Laboratorier AB Prismavägen 2
2 mg/kg daily
2 mg/kg na dan
2 mg/kg every 4 weeks and maintained a paediatric ACR100 response throughout the time the reduced dose was given (median 32 weeks, 8-124 weeks).
2 mg/kg svaka 4 tjedna i održalo pedijatrijski odgovor ACR100 tijekom cijelog razdoblja uzimanja smanjene doze (medijan 32 tjedna, 8-124 tjedana).
2 mg/kg for patients with body weight of 15 kg or more, up to a maximum of 40 kg
2 mg/kg za bolesnike tjelesne težine 15 kg ili više, do najviše 40 kg
2 mg/kg for patients with body weight ≥ 15 kg and ≤ 40 kg
2 mg/kg za bolesnike s tjelesnom težinom ≥15 kg i ≤40 kg
2 mg/kg/day*
2 mg/kg na dan
2 million copies/mL
≤ 2 milijuna kopija/ml
2 mixing cups with joined lids – which are to be used more than once
2 čaše za miješanje s pričvršćenim poklopcima – namijenjene su za višekratnu uporabu
2 ml
butilne gume
2 ml
chloride
2 ml (4 x 0.5 ml doses)
2 ml (4 x 0.5 ml doze)
2 ml (4 x 0.5 ml doses) suspension for injection in a container (Type I glass) with a latex-free grey chlorobutyl rubber stopper and sealed with an aluminum flip-off seal and a polypropylene flip-off cap.
2 ml (4 x 0,5 ml doze) suspenzije za injekcije u spremniku (staklo tipa I) sa sivim čepom od klorobutilne gume koja ne sadrži lateks, zabrtvljena aluminijskim „flip-off” prstenom i polipropilenskim „flip-off” zatvaračem.
2 ml (40 mg) twice daily
2 ml (40 mg) dvaput na dan
2 ml = 1 dose 10 d 20 ml vial
2 ml = 1 doza 10 d bočica od 20 ml
2 ml = 1 dose 25 d 50 ml vial
2 ml = 1 doza 25 d bočica od 50 ml
2 ml = 1 dose 5d 10 ml vial
2 ml = 1 doza 5d bočica od 10 ml
2 ml ampoule white - pink ring
ampula od 2 ml bijeli - ružičasti prsten
2 ml ampoule: colourless neutral glass, Type I.
Ampule od 2 ml: bezbojno neutralno staklo, tipa I.
2 ml ampoules for the use with Venta-Neb:
ampule od 2 ml za primjenu pomoću atomizatora Venta-Neb:
2 ml oral solution in a tube pack size of 1 tube pack size of 10 tubes
2 ml oralne otopine u tubi Pakiranje od 1 tube Pakiranje od 10 tuba
2 ml solution in a colourless type 1 glass ampoule.
2 ml otopine u bezbojnoj staklenoj ampuli (staklo tipa 1).
2 ml Type-1 glass vial stoppered with a laminated rubber stopper and sealed with a flip-off aluminium cap.
Bočica od stakla tipa I od 2 ml začepljena čepom od laminirane gume i zatvorena aluminijskim poklopcem.
2 ml vial
Bočica od 2 ml
2 ml vial (Type I glass) with a stopper (butyl rubber) and a seal (aluminium) with a flip-off cap (polypropylene).
Bočica od 2 ml (staklo tipa I) s čepom (butilna guma) i nepropusnim zatvaračem (aluminij) s kapicom na podizanje (polipropilen).
2 ml vial of solvent.
Bočica otapala od 2 ml
2 ml, by subcutaneous injection (injection given under the skin).
2 ml, subkutanom injekcijom (injekcija koja se daje pod kožu).
2 ml/10 kg bodyweight).
2 ml/10 kg tjelesne mase).
2 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate.
2 ml/100 kg tjelesne težine) u kombinaciji s antibiotskom terapijom, kako je odgovarajuće.
2 mL/pre-filled syringe
2 ml/napunjena štrcaljka
2 months to <3 years
2 mjeseca do <3 godine
2 months –
2 mjeseca
2 needles
+2 igle
2 not evaluated for statistical significance as a part of the sequential confirmatory testing procedure
2 Statistička značajnost nije ocjenjivana zbog provođenja naknadnog testa kao potvrde
2 Not evaluated for statistical significance as a result of the sequential confirmatory testing procedure
2 Statistička značajnost nije ocjenjivana zbog provođenja naknadnog testa kao potvrde
2 Objective Response Rate determined by RECIST v1.1 by BICR in the evaluable for response population (measurable disease at baseline by BICR) n=60,199,199,398 for AURA, AURAex, AURA2 and Overall respectively; NE, not estimable, includes 2 complete responses.
2 Stopa objektivnog odgovora određena prema kriterijima RECIST v1.1 u slijepoj nezavisnoj središnjoj procjeni u populaciji čiji je odgovor moguće procijeniti (bolest na početku liječenja mjerljiva prema slijepoj neovisnoj središnjoj procjeni) n=60 (AURA),199 (AURAex), 199 (AURA2), 398 (sveukupno); NP, nije procjenjivo, uključuje 2 potpuna odgovora.
2 of these cases presented positive re-challenge and a positive de-challenge was noted in 9 cases.
U 2 od navedenih slučajeva zabilježen je pozitivan re- challenge, a u 9 je slučajeva zabilježen pozitivan de-challenge.
2 OJ No L 110 of 26.04.97
2 OJ No L 110 od 05.12.95
2 One adult subject had a positive anti-Factor VIII antibody test result coincident with a single measurement of a neutralising antibody titre of 0.73 Bethesda Units/mL at Week 14.
2 Jedan odrasli ispitanik imao je pozitivan rezultat testa određivanja protutijela na faktor VIII istovremeno s jednim mjerenjem titra neutralizirajućih protutijela od 0,73 Bethesda jedinica/ml u 14. tjednu.
2 Only in the initial combination therapy.
2Samo u početnom kombiniranom liječenju.
2 Only patients who were in MMR at a specific time point are included as responders for that time point.
2 Samo oni bolesnici koji su imali MMR u određenoj vremenskoj točki su uključeni kao osobe s odgovorom za tu vremensku točku.
2 p-value is derived from ANCOVA t-test.
2 p-vrijednost izvedena je iz ANCOVA t-testa.
2 P-value using Fisher’s exact test to compare pegloticase group vs. placebo
2 p-vrijednost određena Fisherovim egzaktnim testom za usporedbu skupine koja je primala peglotikazu naspram skupine koja je primala placebo
2 p< 0.0001 compared to placebo.
2 p< 0,0001 u usporedbi s placebom.
2 Patients and percentage of patients with best overall response of confirmed CR or PR; percentage calculated on patients with measurable disease at baseline
2 Bolesnice i postotak bolesnica s najboljim ukupnim odgovorom koji uključuje potvrđeni djelomičan ili potpun odgovor; postotak izračunat na temelju bolesnica s mjerljivom bolešću na početku ispitivanja
2 patients are listed in Table 1 by System Organ Class.
2 bolesnika navedene su u Tablici 1 prema organskim sustavima.
2 patients died
2 bolesnika su umrla.
2 Patients with missing data were considered as a failure
2 Bolesnici s manjkavim podacima smatrani su neuspjehom
2 Pens
2 brizgalice
2 pens + 24 injection needles + 24 cleansing swabs
2 brizgalice + 24 igle za injekciju + 24 tupfera za čišćenje
2 Per RECIST guidelines, v 1.1.
2 Prema RECIST smjernicama, v 1.1.
2 pipettes
2 pipeta
2 pipettes
2 pipete
2 pipettes 4 pipettes
2 pipete 4 pipete
2 Placebo patients in the 2 Phase III studies in Crohn’s disease, ACCENT I and ACCENT II, received an initial dose of 5 mg/kg infliximab at study start and were on placebo in the maintenance phase.
2 Bolesnici u placebo skupini u dva klinička ispitivanja faze III u Crohnovoj bolesti, ACCENT I i ACCENT II, primili su inicijalnu dozu infliksimaba od 5 mg/kg na početku ispitivanja, dok su u fazi održavanja primali placebo.
2 Plasters
2 flastera
2 powder vials,
2 bočice s praškom
2 Pre-dose is equivalent to Cmin
2 Prije doze odgovara vrijednosti Cmin
2 Pre-dose is equivalent to Cmin
2 “Prije doze” odgovara vrijednosti Cmin
2 pre-filled pen (0.4 ml sterile solution), each with 1 alcohol pad, in a blister.
2 napunjene brizgalice (0,4 ml sterilne otopine), svaka s 1 jastučićem natopljenim alkoholom, u blisteru.
2 pre-filled pen (0.8 ml sterile solution), each with 1 alcohol pad, in a blister.
2 napunjene brizgalice (0,8 ml sterilne otopine), svaka s 1 jastučićem natopljenim alkoholom, u blisteru.
2 pre-filled pens (single-dose)
2 napunjene brizgalice (jednodozne)
2 pre-filled pens of 0.5ml solution 4 pre-filled pens of 0.5ml solution
2 napunjene brizgalice s 0,5 ml otopine 4 napunjene brizgalice s 0,5 ml otopine
2 pre-filled pens.
2 napunjene brizgalice.
2 pre-filled syringes (0.4 ml sterile solution), each with 1 alcohol pad, in a blister.
2 napunjene štrcaljke (0,4 ml sterilne otopine), svaka s 1 jastučićem natopljenim alkoholom, u blisteru.
2 pre-filled syringes (0.8 ml sterile solution), each with 1 alcohol pad, in a blister.
2 napunjene štrcaljke (0,8 ml sterilne otopine), svaka s 1 jastučićem natopljenim alkoholom, u blisteru.
2 pre-filled syringes (single- dose)
2 napunjene štrcaljke (jednodozne)
2 pre-filled syringes + 2 safety needles
2 napunjene štrcaljke
2 pre-filled syringes with needle guard + 2 alcohol wipes (for use by healthcare professionals only)
2 napunjene štrcaljke s pokrovom za iglu + 2 alkoholne vatice
2 produced in WI-38 human diploid lung fibroblasts.
2 proizveden na WI-38 ljudskim diploidnim fibroblastima pluća.
2 Rash includes common terms of skin toxicity, skin exfoliation, exfoliative rash, rash papular, rash pruritic, rash erythematous, rash generalised, rash macular, rash maculo-papular, skin lesion
2 Osip uključuje uobičajene oblike kožne toksičnosti, ljuštenje kože, eksfolijativni osip, papularni osip, pruritični osip, eritematozni osip, generalizirani osip, makularni osip, makulo-papularni osip, kožne lezije
2 Rate based on prolonged-release exenatide spontaneous reports data (unknown denominator).
2 Stopa na temelju podataka iz spontanih prijava za eksenatid s produljenim oslobađanjem (nepoznati nazivnik).
2 RECIST 1.1: Modified Response Evaluation Criteria in Solid Tumours to evaluate tumour burden based on computed tomography (CT)/magnetic resonance imaging (MRI)
2RECIST 1.1: Modified Response Evaluation Criteria in Solid Toumors - Izmijenjeni Kriteriji za procjenu terapijskog odgovora kod solidnih tumora za procjenu opterećenja tumorom na temelju kompjuterizirane tomografije (CT)/magnetske rezonancije (MRI)
2 Relative potency units defined against a reference vaccine.
2 Relativne jedinice. potentnosti, određene prema referentnom cjepivu.
2 Relative to the control arm; stratified hazard ratio.
2 U odnosu na kontrolnu skupinu, stratificirani omjer rizika
2 Reported in one subject after the first Orgalutran dose.
2 Prijavljeno u jedne ispitanice nakon prve doze lijeka Orgalutran.
2 revascularisation.
2 ciljne žile.
2 sachets, each containing 1 cutaneous patch and 1 tube of cleansing gel (50 g).
vrećice, svaka s 1 flasterom za kožu, i 1 tubu gela za čišćenje (50 g).
2 Sacrum region of interest
2 Područje sakralne kralježnice od interesa
2 see also section infection below
2 Vidjeti i dio o infekcijama u nastavku.
2 See section 5.1 for information on bendamustine dose
2Vidjeti dio 5.1 za informacije o dozi bendamustina
2 See section other special populations
2 Vidjeti dio Ostale posebne populacije
2 SEGA responses were confirmed with a repeat scan.
2 odgovori SEGA-e potvrđeni su ponovljenim snimanjem.
2 Severely reduced visual acuity, equivalent to 4 lines or more, within seven days after treatment was reported in 2.1 % of the verteporfin-treated patients in the placebo-controlled ocular Phase III clinical studies and in less than 1 % of patients in uncontrolled clinical studies.
2 Jako smanjena vidna oštrina, koja odgovara smanjenju za najmanje 4 ili više redaka, unutar sedam dana nakon liječenja, zabilježena je u 2,1% bolesnika liječenih verteporfinom u placebo kontroliranim očnim kliničkim ispitivanjima III. faze te u manje od 1% bolesnika u nekontroliranim kliničkim ispitivanjima.
2 single-use pre-filled syringes with needle guard 2 alcohol wipes
2 napunjene štrcaljke za jednokratnu uporabu sa štitnikom za iglu 2 alkoholne vatice
2 solvent vials
2 bočice s otapalom
2 spray bottle: 18 months
Bočica sa 2 potiska: 18 mjeseci
2 spray containers
2 jednodozna spremnika
2 STATEMENT OF ACTIVE SUBSTANCE
2 NAVOĐENJE DJELATNE TVARI
2 sterile 1 mL injection syringes with retractable injection needle 4 alcohol swabs
2 sterilne štrcaljke za injekciju od 1 ml s iglom za injekciju na uvlačenje 4 alkoholom natopljena jastučića
2 sterile matrices (2.5 x 5 cm)
2 sterilne matrice (2,5 x 5 cm)
2 Study C08-002: 3 patients received ESA which was discontinued after eculizumab initiation
2Ispitivanje C08-002: 3 bolesnika primila su sredstvo koje stimulira eritropoezu, čija je primjena obustavljena nakon početka ekulizumaba.
2 SureClick pre-filled pens.
SureClick napunjene brizgalice.
2 syringes with needles
2 štrcaljki i iglama
2 tablespoons) of soft food such as apple sauce, yoghurt, or pudding.
2 velike žlice) mekane hrane kao što je kaša od jabuka, jogurt ili puding.
2 tablets (1 blister strip)
2 tablete (1 blister traka)
2 tablets 4 tablets
2 tablete
2 tablets 4 tablets
2 tablete 4 tablete
2 tablets in the morning and 3 tablets in the evening
2 tablete ujutro i 3 tablete navečer
2 tablets in the morning or 1 (400 mg) tablet in the morning and 2 tablets in the evening or 1 (400 mg) tablet in the evening.
2 tablete ujutro ili 1 (400 mg) tableta ujutro i 2 tablete navečer ili 1 (400 mg) tableta navečer
2 tablets MIRAPEXIN
2 tablete MIRAPEXINA
2 tablets of INCIVO every 8 hours with food.
2 tablete INCIVA svakih 8 sati uz hranu.
2 tablets SIFROL 0.088 mg
2 tablete SIFROLA
2 tablets SIFROL 0.18 mg
2 tablete SIFROLA
2 These are medicinal products within class where similar interactions could be predicted.
2 Ovo su lijekovi iz klase u kojoj se mogu predvidjeti slične interakcije.
2 These pharmacokinetic parameters obtained from the compartmental analysis
2 Ovi farmakokinetički parametri dobiveni su analizom odjeljaka.
2 These reactions were also identified in the pre-approval clinical trials, but do not meet the criteria for Table 1.
2 Ove su reakcije opažene i u kliničkim ispitivanjima prije dobivanja odobrenja za stavljanje u promet, ali ne zadovoljavaju kriterije za uključenje u Tablicu 1.
2 These studies were performed with ritonavir boosted elvitegravir.
2 Ta su ispitivanja provedena s ritonavirom pojačanim elvitegravirom.
2 This adverse reaction was identified through post-marketing surveillance but not observed in randomised controlled clinical trials or the tenofovir disoproxil fumarate expanded access program.
2 Ova nuspojava prepoznata je tijekom praćenja lijeka nakon stavljanja u promet, ali nije opažena u randomiziranim kliničkim kontroliranim ispitivanjima tenofovirdizoproksilfumarata ili programu proširenog pristupa terapiji.
2 This adverse reaction was not observed in the clinical studies of F/TAF containing products but identified from clinical studies or post-marketing experience for emtricitabine when used with other antiretrovirals.
2 Ova nuspojava nije uočena u kliničkim ispitivanjima lijekova koji sadrţe F/TAF, ali je prepoznata u kliničkim ispitivanjima emtricitabina ili tijekom praćenja emtricitabina nakon stavljanja u promet kad se koristio s drugim antiretrovirusnim lijekovima